The estimated Net Worth of Robert Gardner Harrison is at least $672 Tysiąc dollars as of 20 February 2014. Robert Harrison owns over 17,554 units of Myriad Genetics stock worth over $146,117 and over the last 17 years Robert sold MYGN stock worth over $525,579.
Robert has made over 11 trades of the Myriad Genetics stock since 2008, according to the Form 4 filled with the SEC. Most recently Robert exercised 17,554 units of MYGN stock worth $232,591 on 20 February 2014.
The largest trade Robert's ever made was exercising 38,446 units of Myriad Genetics stock on 6 November 2012 worth over $534,784. On average, Robert trades about 8,007 units every 87 days since 2008. As of 20 February 2014 Robert still owns at least 5,560 units of Myriad Genetics stock.
You can see the complete history of Robert Harrison stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum oraz Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: